GT Medical Technologies, a company focused on improving the lives of patients with brain tumors, today announced the interim results from its ROADS clinical trial (Randomized Controlled Trial of ...
The FDA has approved Libtayo for the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation.
In the U.S., the generic name for Libtayo in its approved indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance ...
Where public-health policy is concerned, it makes sense to be conservative. But when we try too hard, we may actually do more harm than good. An egregious example is our policy on low-level ionizing ...
FDA approves Regeneron's Libtayo for adults with high-risk cutaneous squamous cell carcinoma after surgery and radiation, ...
Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to ...
Dräger, an international leader in the fields of medical and safety technology, announced the release of the Dräger X-site Live, a state-of-the-art area monitoring kit for gas and radiation hazard ...
The FDA has granted approval to adjuvant cemiplimab treatment for patients with high-risk cutaneous squamous cell carcinoma ...
NFPA diamond. Laboratory personnel shall fill in the diamond with the highest hazard number pertaining to their laboratory. Biohazard label and appropriate Biosafety Level (if applicable). UV Light ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback